Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

NCT00720941 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1110

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: Pazopanib
DRUG: Sunitinib

Sponsor

Novartis Pharmaceuticals